Legend Biotech (LEGN) reports earnings today following a 30% surge in its stock price over the past month. Despite this rally, the company maintains short interest above 8% of the free float. This creates an unusual setup where the lending market remains sensitive to price action. There is no 13D activist on the register, suggesting the current short pressure is commercial rather than governance-driven. The stock's recent performance has drawn significant retail attention, with Wikipedia z-scores spiking in mid-October. Today's print will test whether the commercial trajectory of CARVYKTI is robust enough to sustain the current valuation.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.